Researchers at the National Institutes of Health (NIH) and their collaborators at Beren Therapeutics, Thousand Oaks, California, have developed a treatment for infants with Niemann-Pick type C (NPC) disease, which is a rare and rapidly fatal pediatric neurodegenerative disorder. The drug, known as cyclodextrin (brand name Adrabetadex), extended the survival of participants with NPC in a large, international clinical trial and represents foundational scientific research efforts that began 20 years ago. The drug was approved by the U.S. Food and Drug Administration (FDA) on Nov. 17, 2026.
Getting Started is Easy and Yes It's FREE
What is The Ecosystem?
The Token Revolution.
The Next Bitcoin Moment.
